This targeted RNA sequencing panel is a cost-effective solution to detect gene fusions in multiple cancer types, regardless of origin. Covering 507 fusion-associated genes, a single assay enables researchers to assess most known cancer-related fusions in blood, bone marrow, and FFPE samples, with the power to identify novel fusion gene partners.
- Industry-validated content for a comprehensive view of cancer-related fusion genes, detecting common and novel fusions
- From RNA to results in 4 days including on-instrument software that displays fusion calls
- Compatibility with desktop sequencers to maximize lab budgets
- Optimized RNA sequencing for all sample types, including FFPE tissues
Simple Fusion Report for Customers New to NGS
On-instrument fusion calling provides NGS-based fusion detection to labs without additional bioinformatics support. The analysis provides a list of detected fusions, relevant disease associations (as identified by the Mitelman database), and evidence of fusion-supporting reads.
Robust, Reproducible, and Low-Input Fusion Assay
This assay accommodates as little input as 20 ng FFPE RNA or 10 ng fresh-frozen total RNA. The TruSight RNA Fusion Panel provides a sensitive, reproducible, and economical solution for studies of gene fusions in cancer research.